Kolexia
Schulmann Samantha Hématologie
Schulmann Samantha
Hématologie
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
23 Activités
202 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Dexaméthasone Immunomodulateurs Inhibiteurs du protéasome Facteurs immunologiques Proteasome endopeptidase complex {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Perrot Aurore
Perrot Aurore
Oncopole Toulouse, Toulouse, France
Moulin Charline
Moulin Charline
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Ziegler Caroline
Ziegler Caroline
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Janssen
16 collaboration(s)
Dernière en 2023
Sanofi
2 collaboration(s)
Dernière en 2023
Pfizer
2 collaboration(s)
Dernière en 2023
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
EJHaem   13 décembre 2023
Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
2022 ASCO Annual Meeting I   02 juin 2022
POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France
Emerging Frontiers and Opportunities 2022   01 janvier 2022
Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)
Blood   23 novembre 2021
RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?
Blood   23 novembre 2021
Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort
Blood   23 novembre 2021
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}